These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 25839629)

  • 1. Incidence of ventricular arrhythmias during World Cup football 2014 in patients with implantable cardioverter defibrillator.
    Kondo Y; Linhart M; Schwab JO; Andrié RP
    Int J Cardiol; 2015; 187():307-8. PubMed ID: 25839629
    [No Abstract]   [Full Text] [Related]  

  • 2. Residual high incidence of ventricular arrhythmias after left ventricular reconstructive surgery.
    O'Neill JO; Starling RC; Khaykin Y; McCarthy PM; Young JB; Hail M; Albert NM; Smedira N; Chung MK
    J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1250-6. PubMed ID: 16256775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of COVID-19 on the incidence of cardiac arrhythmias in implantable cardioverter defibrillator recipients followed by remote monitoring.
    Galand V; Hwang E; Gandjbakhch E; Sebag F; Marijon E; Boveda S; Leclercq C; Defaye P; Rosier A; Martins RP
    Arch Cardiovasc Dis; 2021 May; 114(5):407-414. PubMed ID: 34088625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical profile and incidence of ventricular arrhythmia in patients undergoing defibrillator generator replacement in Spain.
    Fontenla A; López Gil M; Martínez Ferrer J; Alzueta J; Fernández Lozano I; Viñolas X; Rodríguez A; Fernández de la Concha J; Anguera I; Arribas F
    Rev Esp Cardiol (Engl Ed); 2014 Dec; 67(12):986-92. PubMed ID: 25432708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An impaired renal function and advanced heart failure represent independent predictors of the incidence of malignant ventricular arrhythmias in patients with an implantable cardioverter/defibrillator for primary prevention.
    Kreuz J; Balta O; Linhart M; Fimmers R; Lickfett L; Mellert F; Nickenig G; Schwab JO
    Europace; 2010 Oct; 12(10):1439-45. PubMed ID: 20817721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ventricular oversensing due to manufacturer-related differences in implantable cardioverter-defibrillator signal processing and sensing lead properties.
    Seegers J; Zabel M; Lüthje L; Vollmann D
    Europace; 2010 Oct; 12(10):1460-6. PubMed ID: 20663783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology, management, and outcomes of sustained ventricular arrhythmias after continuous-flow left ventricular assist device implantation.
    Raasch H; Jensen BC; Chang PP; Mounsey JP; Gehi AK; Chung EH; Sheridan BC; Bowen A; Katz JN
    Am Heart J; 2012 Sep; 164(3):373-8. PubMed ID: 22980304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry).
    Kutyifa V; Moss AJ; Klein H; Biton Y; McNitt S; MacKecknie B; Zareba W; Goldenberg I
    Circulation; 2015 Oct; 132(17):1613-9. PubMed ID: 26316618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of implantable cardioverter-defibrillators on mortality among patients on the waiting list for heart transplantation.
    Grimm M; Wieselthaler G; Avanessian R; Grimm G; Schmidinger H; Schreiner W; Podczeck A; Wolner E; Laufer G
    J Thorac Cardiovasc Surg; 1995 Aug; 110(2):532-9. PubMed ID: 7637372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Spanish implantable cardioverter-defibrillator registry. Seventh official report of the spanish society of cardiology working group on implantable cardioverter-defibrillators (2010)].
    Alzueta J; Fernández JM
    Rev Esp Cardiol; 2011 Nov; 64(11):1023-34. PubMed ID: 21967881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ventricular arrhythmias due to left ventricular noncompaction cardiomyopathy: a diagnosis in hindsight.
    Liang JJ; McKenzie KM; Cha YM
    Heart Lung Circ; 2014 Feb; 23(2):e67-8. PubMed ID: 23791713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cardiac resynchronisation therapy on occurrence of ventricular arrhythmia in patients with implantable cardioverter defibrillators undergoing upgrade to cardiac resynchronisation therapy devices.
    Lin G; Rea RF; Hammill SC; Hayes DL; Brady PA
    Heart; 2008 Feb; 94(2):186-90. PubMed ID: 17761506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does right ventricular pacing increase the risk of ventricular arrhythmias in patients with an implantable cardioverter-defibrillator?
    Josiak K; Nowak K; Fuglewicz A; Jagielski D; Banasiak W; Ponikowski P
    Kardiol Pol; 2014; 72(4):381-4. PubMed ID: 24733700
    [No Abstract]   [Full Text] [Related]  

  • 15. Increased incidence of life-threatening ventricular arrhythmias in implantable defibrillator patients after the World Trade Center attack.
    Steinberg JS; Arshad A; Kowalski M; Kukar A; Suma V; Vloka M; Ehlert F; Herweg B; Donnelly J; Philip J; Reed G; Rozanski A
    J Am Coll Cardiol; 2004 Sep; 44(6):1261-4. PubMed ID: 15364329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable cardioverter-defibrillator after left ventricular reconstruction?
    Sartipy U; Albåge A; Lindblom D
    J Thorac Cardiovasc Surg; 2006 May; 131(5):1210-1; author reply 1211. PubMed ID: 16678631
    [No Abstract]   [Full Text] [Related]  

  • 17. Gender differences in device therapy for malignant ventricular arrhythmias.
    Horton HL; Marinchak RA; Rials SJ; Kowey PR
    Arch Intern Med; 1995 Nov; 155(21):2342-5. PubMed ID: 7487260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of ventricular arrhythmia burden, therapeutic interventions, and survival, in patients < 75 and patients >or= 75 years of age treated with implantable cardioverter defibrillators.
    Ermis C; Zhu AX; Vanheel L; Sakaguchi RN; Lurie KG; Lu F; Benditt DG
    Europace; 2007 May; 9(5):270-4. PubMed ID: 17371804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implantable cardioverter defibrillator prevents sudden cardiac death in systemic sclerosis.
    Bernardo P; Conforti ML; Bellando-Randone S; Pieragnoli P; Blagojevic J; Kaloudi O; Guiducci S; Porta F; Padeletti L; Gensini GF; Matucci-Cerinic M
    J Rheumatol; 2011 Aug; 38(8):1617-21. PubMed ID: 21632680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.
    Kreuz J; Skowasch D; Horlbeck F; Atzinger C; Schrickel JW; Lorenzen H; Nickenig G; Schwab JO
    Am J Cardiol; 2013 May; 111(9):1319-23. PubMed ID: 23411108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.